Wedbush raised its price target on Karyopharm Therapeutics (NASDAQ: KPTI) to $21.00 (from $19.00) while maintaining a Outperform rating.Analyst ​David ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Karyopharm Therapeutics (KPTI) Prices 9.15M Share Common Offering at $14.75/ShMay 3, 2018 5:37 AM Karyopharm Therapeutics (KPTI) PT Raised to $25 at Cantor FitzgeraldMay 2, 2018 3:48 AM Karyopharm Therapeutics (KPTI) PT Raised to $24 at RBC Capital; 'We Would Be Buyers'May 1, 2018 7:58 AM Karyopharm Therapeutics (KPTI) PT Raised to $24 at Leerink PartnersMay 1, 2018 1:34 AM After-Hours Stock Movers 04/30: (KPTI) (INGN) (NTRI) Higher; (CGNX) (IVAC) (RIG) Lower (more...)April 30, 2018 6:27 PM Form 8-K Karyopharm Therapeutics For: Apr 30April 30, 2018 4:22 PM Karyopharm Therapeutics (KPTI) to Resume Trading at 4:35 pm ETApril 30, 2018 4:16 PM UPDATE: Karyopharm (KPTI) Says Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Achieved 25.4% ORRApril 30, 2018 4:08 PM Karyopharm Announces Positive Top-Line Data from Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Multiple MyelomaApril 30, 2018 4:05 PM